-

iHealthScreen’s Artificial Intelligence (AI) Based Tool Can Accurately Diagnose Age-Related Macular Degeneration (AMD) and Help Prevent Blindness

Prospective Study Presented at the Annual Meeting of the American Academy of Ophthalmology (AAO), November 13-15, 2020.

  • Selected for the AAO 2020 panel discussion as one of the outstanding works
  • First prospective clinical study on AI and color retinal image based early diagnosis of AMD in outpatient settings
  • 88.7% accuracy achieved on 503 fundus images of 299 patients followed-up prospectively

RICHMOND HILL, N.Y.--(BUSINESS WIRE)--iHealthScreen CEO Alauddin Bhuiyan, Ph.D. along with collaborators at New York Eye and Ear Infirmary at Mount Sinai (NYEEI), presented a prospective study for early diagnosis of AMD at the annual conference of AAO, 2020. The results presented during the prestigious Original Paper Session demonstrated 88.7% accuracy, compared to ophthalmologist gradings, on detecting referable AMD.

AMD, with no early signs or symptoms, is a leading cause of adult blindness in the developed world. Early detection can enable preventative measures in time and stop AMD incident. Currently, AMD diagnosis has been limited to retinal examination by an ophthalmologist. AMD cases in the U.S. are expected to grow from 2.1 million to 5.4 million in the next ten years, and there is an increasing need for large scale screening and identification of individuals who are at risk of developing late AMD. iHealthScreen’s AI based tool can facilitate this screening and help prevention of late AMD.

In an interview, Dr. Bhuiyan spoke about the study and the findings: “We are encouraged by the results and believe that the new AI-based technology can diagnose early AMD in primary care settings, which enables the timely preventative measures by ophthalmologist and prevent this deterioration of vision. We want to express our sincerest thanks to the participants and professional staff who were involved in this clinical trial and gathered the data.”

“These results speak to the feasibility of this approach,” said Theodore Smith, M.D., Ph.D., Trial’s Principal-investigator and Professor at Icahn School of Medicine at Mount Sinai. “I believe that the ease of use of iHealthScreen’s AI tool will contribute to its adoption in the wider primary care community.”

About iHealthScreen

iHealthScreen is a private, clinical-stage, medical diagnostic/device company. iHealthScreen has developed iPredict, an AI and telemedicine-based HIPAA compliant platform for automated screening and prediction of individuals at risk of developing late age-related AMD, diabetic retinopathy (DR), glaucoma, cardiovascular heart disease and stroke.

Contacts

Klara Czobor
Director of Investor Relations & Corporate Communications, iHealthScreen
Email: klara@ihealthscreen.org
Phone: 201.232.6182

iHealthScreen


Release Summary
AAO Press Release
Release Versions

Contacts

Klara Czobor
Director of Investor Relations & Corporate Communications, iHealthScreen
Email: klara@ihealthscreen.org
Phone: 201.232.6182

More News From iHealthScreen

iHealthScreen Developed and Validated Risk Prediction Models for Cardiovascular Diseases Using Individual’s Retinal Color Images and Health Data

NEW YORK--(BUSINESS WIRE)--iPredict™ Stroke and heart attack prediction models provide AI-based automated prediction scores for incident stroke and heart attack (i.e., myocardial infarction (MI)) which identifies the individuals who are at risk of having stroke and MI within 5 years. These results were peer-reviewed and accepted by the scientific review team and will be presented at the ESC Congress which will be held between 30th August and 2nd September 2024. The iPredict stroke and MI predic...

iHealthScreen Inc. is Awarded a US Patent on Glaucoma Detection, Which Is Based on AI and Color Fundus Imaging

NEW YORK--(BUSINESS WIRE)--iPredictTM glaucoma detection model provides a fully automated detection report for glaucoma which can be implemented in the primary care settings for screening and detection of early-stage glaucoma. The full US patent was awarded by USPTO on March 26, 2024. Earlier the results were published in a scientific journal and the results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024. The early screening and detection of glaucoma c...

iHealthScreen Inc. Announces UK Medicines and Healthcare Products Regulatory Agency (MHRA) Certification and registration for iPredict™ - Automated AI System for Early Diagnosis of DR, AMD, and Glaucoma

NEW YORK--(BUSINESS WIRE)--Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR), Age-Related Macular degeneration (AMD), and Glaucoma, and help prevent blindness...
Back to Newsroom